These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
483 related items for PubMed ID: 14749143
21. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. Pham DQ, Nogid A, Plakogiannis R. Am J Health Syst Pharm; 2008 Mar 15; 65(6):521-31. PubMed ID: 18319497 [Abstract] [Full Text] [Related]
22. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al. Hamid Z, Simmons DL. Diabetes Care; 2006 Oct 15; 29(10):2331; author reply 2332. PubMed ID: 17003324 [No Abstract] [Full Text] [Related]
23. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Ryan GJ, Jobe LJ, Martin R. Clin Ther; 2005 Oct 15; 27(10):1500-12. PubMed ID: 16330288 [Abstract] [Full Text] [Related]
27. Metformin and other antidiabetic agents in renal failure patients. Lalau JD, Arnouts P, Sharif A, De Broe ME. Kidney Int; 2015 Feb 15; 87(2):308-22. PubMed ID: 24599253 [Abstract] [Full Text] [Related]
28. Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Bailey CJ, Day C. Int J Clin Pract; 2004 Sep 15; 58(9):867-76. PubMed ID: 15529521 [Abstract] [Full Text] [Related]
29. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P. Diabetes Care; 2003 Jul 15; 26(7):2069-74. PubMed ID: 12832315 [Abstract] [Full Text] [Related]
30. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. N Engl J Med; 2006 Dec 07; 355(23):2427-43. PubMed ID: 17145742 [Abstract] [Full Text] [Related]
31. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Mamza J, Mehta R, Donnelly R, Idris I. Ann Med; 2016 Dec 07; 48(4):224-34. PubMed ID: 26982210 [Abstract] [Full Text] [Related]
33. Inhaled dry powder insulin for the treatment of diabetes mellitus. Setter SM, Levien TL, Iltz JL, Odegard PS, Neumiller JJ, Baker DE, Campbell RK. Clin Ther; 2007 May 07; 29(5):795-813. PubMed ID: 17697900 [Abstract] [Full Text] [Related]
34. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Melchior WR, Jaber LA. Ann Pharmacother; 1996 Feb 07; 30(2):158-64. PubMed ID: 8835050 [Abstract] [Full Text] [Related]
36. The use of insulin alone and in combination with oral agents in type 2 diabetes. Buse JB. Prim Care; 1999 Dec 07; 26(4):931-50. PubMed ID: 10523468 [Abstract] [Full Text] [Related]
37. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Med Sci (Basel); 2023 Aug 15; 11(3):. PubMed ID: 37606429 [Abstract] [Full Text] [Related]
38. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group, RECORD Steering Committee. Diabetologia; 2010 Sep 15; 53(9):1838-45. PubMed ID: 20532476 [Abstract] [Full Text] [Related]
39. Rosiglitazone : a review of its use in type 2 diabetes mellitus. Deeks ED, Keam SJ. Drugs; 2007 Sep 15; 67(18):2747-79. PubMed ID: 18062722 [Abstract] [Full Text] [Related]
40. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. J Clin Endocrinol Metab; 2013 Feb 15; 98(2):668-77. PubMed ID: 23372169 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]